Cargando…
Real-World Impact of Switching From Insulin Glargine (Lantus(®)) to Basaglar(®) and Potential Cost Saving in a Large Public Healthcare System in Saudi Arabia
BACKGROUND: The advent of Basaglar(®), which is a biosimilar insulin glargine formulation for Lantus(®) has brought hope that it will result in similar outcomes and lower costs. However, some health practitioners raised some concerns about the therapeutic equivalence of this new biosimilar. Therefor...
Autores principales: | AlRuthia, Yazed, Bahari, Ohud H., Alghnam, Suliman, Alrumaih, Ali M., Asiri, Hassan, Alshammari, Mohammed, Alhowimel, Mansour, Al-Abdulkarim, Hana A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234164/ https://www.ncbi.nlm.nih.gov/pubmed/35769787 http://dx.doi.org/10.3389/fpubh.2022.852721 |
Ejemplares similares
-
Basaglar
por: Newsome, Cheyenne
Publicado: (2017) -
The Impact of COVID-19 on Essential Medicines and Personal Protective Equipment Availability and Prices in Saudi Arabia
por: Aljadeed, Rana, et al.
Publicado: (2021) -
The Commonly Utilized Natural Products during the COVID-19 Pandemic in Saudi Arabia: A Cross-Sectional Online Survey
por: AlNajrany, Sina M., et al.
Publicado: (2021) -
How can Saudi Arabia reform its public hospital payment models? A narrative review
por: AlRuthia, Yazed, et al.
Publicado: (2020) -
Estimation Of Direct Medical Costs Of Middle East Respiratory Syndrome Coronavirus Infection: A Single-Center Retrospective Chart Review Study
por: AlRuthia, Yazed, et al.
Publicado: (2019)